Background: Studies have demonstrated that statin therapy decreases the growth rate of abdominal aneurysms. However, the effect of statin therapy on the proximal aortic disease has not been sufficiently elucidated. Aim: We aimed to analyse the association between statin treatment and the severity of proximal aortopathy in patients with aortic valve disease. Design: Cross-sectional study. Methods: We prospectively identified 458 patients who were referred for aortic valve surgery from 2008 to 2014. Preoperative measurement of the proximal aorta was performed by TEE, CT or MRT scan. Data of dyslipidemia treatment was obtained by questionnaire. Results: The mean ascending aortic diameter in the whole study population was comparable in patients with vs. without statin therapy (i.e. 42.7 mm vs. 43.6 mm, P ¼ 0.46). Logistic regression analysis showed no significant association between statin therapy and proximal aortopathy 40 mm in the whole study group (OR ¼ 0.69, P ¼ 0.10). For the BAV sub-group, HDL (OR ¼ 0.54, P ¼ 0.038) and cholesterol levels (OR ¼ 2.00, P ¼ 0.038) were found significantly associated with the proximal aortic disease. In the BAV cohort, the statin users with target HDL levels presented a significantly smaller proximal aortic diameter (40.1 mm vs. 46 mm, P ¼ 0.02). Conclusion: Pre-operative statin therapy demonstrated no significant association with the expression of proximal aortopathy. However, more than 40% of the statin users presented uncontrolled lipid levels at the time of the study. In the BAV sub-group, the statins users with target HDL levels showed a significantly smaller ascending aorta diameter. Target HDL and cholesterol levels were strongly associated with proximal aortic dilation in BAV patients.
Background
Despite major advances in the diagnostic and treatment of aortic diseases, ascending aortic aneurysm remains a vasculopathy with significant challenges in the cardiovascular medicine.
Aortic aneurysm develops as a sequel of synergistic effect of interacting stressors consisting of genetic pre-disposition, increased wall shear stress in the aortic wall, proteolytic extracellular matrix (ECM) degradation and/or inflammatory/autoimmune response. 1 Over the last decades, a number of factors associated with the development of proximal aortopathy have been identified, including age, connective tissue disorders and aortic valve morphology. 1 Several previous studies demonstrated that patients with a bicuspid valve (BAV) have a higher risk of developing an ascending aortic aneurysm. 2 Despite a better understanding of the pathophysiology of proximal aortic disease, there are no established pharmaceutical options available to affect the natural history of aortopathy. 3 Recent studies suggested that statin therapy might be associated with a reduced risk of proximal aortic growth. [4] [5] [6] Statins reduce the synthesis of cholesterol by competitively inhibiting HMG-CoA reductase activity 7, 8 and have been shown to exhibit pleiotropic effects, including improvement of endothelial function, increased nitric oxide bioavailability, anti-inflammatory and anti-oxidant effects. 9 Regarding their potential vascular effects, statins may counteract aortic dilation by limiting the adverse effects of metabolic syndrome and by restoring matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) balance. 9, 10 We aimed to prospectively analyse the association between statin use and expression of the proximal aortopathy in a consecutive cohort of patients referred for surgery due to aortic valve disease.
Materials and methods

Inclusion and exclusion criteria
We prospectively analysed 458 consecutive patients who were referred for aortic valve surgery with/without proximal aortic replacement, from January 2008 through to December 2014. We identified those patients who had proximal aortic dimensions quantitatively measured by pre-operative computer tomography (CT), magnetic resonance imaging (MRI) or transesophageal echocardiogram (TOE). Valve morphology was defined according to the intra-operative description by the attending surgeon.
Patients with known connective tissue disorders, dialysisdependent end-stage renal failure and combined surgical procedures (i.e. including coronary artery bypass, concomitant mitral or tricuspid valve surgery) were excluded from this study. Furthermore, patients who underwent urgent/emergent surgical procedures (e.g. acute aortic dissection or endocarditis) were also excluded.
Statin use and serum lipids detection from blood sample
The information on the pre-operative statin therapy, including the specific agent (e.g. simvastatin, atorvastatin, fluvastatin or pravastatin) and dosage was obtained through pre-operative questionnaire. All lipid levels were measured pre-operatively. The plasma concentration of triglycerides, cholesterol and highdensity lipoprotein cholesterol (HDL) were measured using an enzymatic colorimetric method (Roche diagnostics, Mannheim, Germany). Low-density lipoprotein cholesterol (LDL-chol) was calculated according to the computational procedures of Friedwald. 11 The measured values of total cholesterol, triglycerides and HDL-cholesterol were used according to the relationship:
Statistical analysis
Continuous variables are presented as mean 6 standard deviation; categorical data is expressed as numbers and percentages. Univariate comparisons of continuous variables were made using the two-sample t-test, and x 2 test or Fischer exact test was used for the categorical variables. Multi-variate logistic regression was used to identify independent variables associated with the proximal aortic diameter 40 mm, and included variables with P < 0.1 in the univariate analysis. The P-values were considered statistically significant when < 0.05. All statistical analyses were performed with the IBM SPSS 19.0 software (IBM corp., New York, NY, USA).
Results
Study population
A total of 458 patients met the inclusion criteria and served as our study population. Figure 1 ). Subsequently, to determine the efficacy of the administrated statin we classified the patients into two sub-groups: patients within target LDL levels vs. patients out of target LDL levels ( Figure 1 ). AACE 2017 Guideline was used to define the target levels of each lipid markers (i.e. LDL <100 mg/dl, cholesterol <200 mg/dl, HDL in women >50 mg/dl, HDL in men >40 mg/dl, triglycerides <150 mg/dl). 12 More than 40% of the whole study population Demographics and pre-operative characteristics of the whole study population were sub-divided into statin users vs. non-statin users and are presented in Table 1 . The severity of aortopathy was comparable between both sub-groups. Proximal aortic diameter was 42.7 6 9.5 mm in statin-users vs. 43.6 6 8.6 mm in non-statin users (P ¼ 0.46). The remaining pre-operative variables, including the most common comorbidities [i.e. diabetes, chronic obstructive lung disease (COLD) and history of smoking], were comparably distributed in the both study subgroups.
We found no significant association between aortic dilatation (i.e. aortic diameter 40 mm) and the effectivity of lipid control in the whole study cohort (Table 2 ). In a multi-variable logistic regression model including statin therapy, categorized lipid markers, and age as variables, only age was identified as an independent predictor of proximal aortic diameter 40 mm (OR¼ 1.02, P ¼ 0.025; Table 3A ).
BAV cohort
Sub-group analysis of the BAV cohort demonstrated a significant association between proximal aortopathy and HDL levels (P ¼ 0.027; Table 2 ). Patients who had low levels of high-density lipoprotein showed higher ascending aortic size (i.e. 45.0 mm vs. 42.6 mm). Further analysis revealed that statin users with target HDL levels presented a significantly smaller proximal aortic diameter, compared to the out of target HDL patients (i.e. 40.1 6 7.5 mm vs. 46.0 6 8.5 mm, P ¼ 0, 02; Figure 2 ). The nonstatin users, on the contrary, showed a comparable mean ascending aorta diameter for both sub-groups (i.e. target HDL levels: 43.4 6 7.2 mm vs. out of target HDL levels: 44.5 6 7.9 mm, P ¼ 0.48; Figure 3 ). In the logistic regression analysis performed selectively in the BAV cohort, we identified cholesterol (OR¼ 2.00, P ¼ 0.038) and once again HDL levels (OR¼ 0.55, P ¼ 0.038) as significant factors associated with aortic dilatation 40 mm (Table 3B) . Of note, statin therapy showed no significant association with the proximal aortopathy (OR¼ 0.65, P ¼ 0.17).
TAV cohort
In the TAV cohort no association was found between lipid levels and proximal aortic dilatation 40 mm (Table 3C ). Once again, regardless of the statin use, most of the TAV patients presented out of range LDL and HDL levels ( Figure 1) . In logistic regression analysis preformed for the TAV sub-group, statin therapy showed no significant association with the proximal aortopathy. Only age was found to be an independent factor associated with aortic diameter 40 mm (OR¼ 1.44, P ¼ 0.01; Table 3C ).
Discussion
Our main finding indicates that pre-operative statin therapy is not independently associated with the expression of proximal aortopathy. However, more than 40% of the statin users presented uncontrolled lipid levels at the time of the study. Of note is that statins users with target HDL levels in the BAV sub-group presented a significantly smaller ascending aorta diameter.
Aortic aneurysm is a complex and multi-factorial disease, with both genetic and environmental risk factors which contribute to the underlying pathobiology. 3 Recent studies suggested that statin therapy might be related to the reduction in the progression rate of proximal aortopathy. [4] [5] [6] In the logistic regression preformed for our study population, we did not found any association between statin use and proximal aortopathy. Our results corroborate the findings of Jovin et al., who concluded that statin therapy cannot reduce the progression of proximal aorta aneurysm but it can lower the rate of death. An important limitation of these studies is the fact that serum lipid levels were not taken into consideration. Not allowing the reachers to examine whether a target lipid level under statin therapy is associated with a better outcome or smaller aortic diameter. 13 In contrast to our results, Angeloni et al. found that there is a significant association between statin use and the growth rate of the ascending aorta aneurysm. 5 However, several methodological differences exist between our present study and that published by Angeloni et al. The most important difference between the two studies is the control of statin therapy based on target lipid levels. Patients who participated in the Angeloni study received a statin therapy which was adapted to their plasma lipid levels over a period of 3 years. If needed, the statin dose was increased to reach a therapeutic goal of LDL <100 mg/dl. Additionally, 'non-compliant' patients with an inconsistent therapy administration were excluded. 5 This study indicates that in order to be a protective medication, statin therapy has to be adapted to target lipid levels. Furthermore, recent in vivo and in vitro studies have also shown that the protective effects of statin are dose-dependent. 14 In order to determine the efficacy of the administrated statin we classified our statin users based on the target lipid levels (Table 1) . Surprisingly, we observed that more than 40% of our patients continued to have out-of-target lipid levels after taking statin. In fact, there was no significant difference in the mean values of lipid markers between the statin users vs. non-users. From this we can assume that the statin dose was perhaps too low for patients who presented an out of target lipid level, and therefore they could not benefit from the protective effects of statin therapy. In order to test this we would have to conduct further studies. For this reason, our study is not completely comparable with that of Angeloni et al. While Angeloni's study was performed over a 3-year period, we were only able to evaluate the statin influence on the proximal aortic diameter in a cross-sectional study.
The second most important result of our study is related to the BAV group. It is well documented that BAV patients have a more complex interaction than TAV patients, with regard to the genotypes, environmental risk factors and specific hemodynamic conditions created by bi-cuspid aortic valve anatomy. 15 Our data demonstrated that proximal aortic diameter 40 mm in bicuspid patients is strongly associated with HDL and cholesterol levels (Table 3B) . Normal or high levels of highdensity lipoprotein protect the BAV patients from a larger diameter of the ascending aorta (42.6 mm vs. 45.0 mm). In our logistic regression, we also found that statin treatment was not associated with proximal aortopathy (Table 3B ). However, we have to emphasize that most of our statin users did not present target levels at the time of the study. Interestingly, we observed that statin users with target HDL levels showed a significantly smaller proximal aortic size compared to the out of target HDL levels (40.1 mm vs. 46 mm). In contrast, both sub-groups (i.e. patient with and with out of target HDL levels) of the non-statin users presented similar aortic size. On a histological level, BAV patients do not present many atherosclerotic changes or plaques in the aortic wall. 16 Nonetheless, it also seems reasonable to speculate that out-oftarget levels of cholesterol and HDL could indirectly contribute to the progress of proximal aortic aneurysm. The relationship between aneurysm in BAV patients and atherosclerosis could be due to the hemodynamic shear stress of the bi-cuspid valve. 17 There is substantial evidence to suggest that disturbed flow can alter the profile of extracellular (EC) molecule expression which can lead to the development of microscopic atherosclerotic lesions, thrombosis and EC dysfunction. 17 All these alterations leave the proximal aortic wall more vulnerable to disturbed flow, creating a vicious circle that then leads to a progressive dilation of the wall. In order to minimize the development of microscopic atherosclerotic lesions, all lipid levels should be within target levels, especially cholesterol and HDL. As presented in our results, HDL was the most important lipid marker associated with dilation in BAV patients. It is important to highlight that HDL did not just have atheroprotective properties, but also anti-oxidant, anti-inflammatory and anti-thrombotic effects on the aortic wall. 18, 19 Therapies targeting HDL could potentially slow the progression of proximal aneurysm. Taking this into consideration, we can suggest that statin therapy may reduce the risk of proximal aortic aneurysm in BAV patients, by raising the levels of HDL by almost 15%, reducing noxious lipids levels (i.e. cholesterol and LDL) and restoring MMPs/TIMPs balance. 20 Regeer et al. also supports this hypothesis. In their study of 199 patients with bicuspid aortic valve, the authors were able to demonstrate that statin use was associated with smaller diameters of the proximal aorta. 21 In accordance with these findings, another recent study published by Goel et al. found that statin use was the only independent predictor of aortic size and was associated with a 0.33-cm reduction in BAV patients. 22 Our last results confirm that age is still a predictor for the TAV group and the whole study population. Stiffening of the proximal aorta has been shown to be strongly related to aging and is also one of the earliest manifestations of vascular aging in otherwise healthy humans. 23 Structural and functional changes of the aortic wall during the aging can lead to geometric and functional changes of the proximal aorta. 24 In summary, our data suggest that statin use is not significantly associated with the expression of proximal aortopathy in any of our study cohorts. However, more than 40% of the statin users presented uncontrolled lipid levels at the time of the study. We also concluded that HDL and cholesterol levels are associated with the proximal aortic dilation in BAV patients. In addition to this we confirm that statin users with HDL target levels presented a smaller ascending aortic diameter. Suggesting that statin therapy has to be adapted to target levels in order to be a protective medication. For the TAV cohort and whole study population, age is still a major predictor for proximal aortopathy.
Nevertheless, our present study has important limitations. Our study is a cross-sectional analysis and so, the longitudinal effects of statin therapy on the aortopathy progression cannot be assessed. Additionally, we found significant heterogeneity in the statin therapy when it was not adapted to the target lipid levels. Furthermore, the fact that we did not know when the therapy started and with what regularity it was taken can be considered another limitation. More extensive prospective longitudinal studies are required to assess the effect of statin administration in the proximal aortic dilation, especially in BAV patients.
